<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04033328</url>
  </required_header>
  <id_info>
    <org_study_id>ORIC-101-02</org_study_id>
    <nct_id>NCT04033328</nct_id>
  </id_info>
  <brief_title>Study of ORIC-101 in Combination With Enzalutamide</brief_title>
  <official_title>An Open-Label Phase 1b Study of ORIC-101 in Combination With Enzalutamide in Patients With Metastatic Prostate Cancer Progressing on Enzalutamide</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oric Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oric Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to establish the recommended phase 2 dose (RP2D), safety,&#xD;
      pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of ORIC-101&#xD;
      in combination with enzalutamide (Xtandi®) when administered to patients with metastatic&#xD;
      prostate cancer progressing on enzalutamide.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      ORIC-101 is a small molecule GR antagonist being developed for the treatment of patients with&#xD;
      solid tumor malignancies. Mechanistically, ORIC-101 inhibits GR transcriptional activity and&#xD;
      blocks the pro-survival signals mediated by the activated nuclear receptor.&#xD;
&#xD;
      This is an open-label, single arm, multicenter, dose escalation followed by dose expansion&#xD;
      study to assess the safety and preliminary antitumor activity of ORIC-101 in combination with&#xD;
      enzalutamide in patients progressing on enzalutamide. Patients deemed eligible will receive&#xD;
      treatment with ORIC-101 in addition to continuing their current enzalutamide therapy.&#xD;
&#xD;
      Escalating dose levels of ORIC-101 will be administered orally, once daily in combination&#xD;
      with enzalutamide 160 mg. Parallel enrollment for assessment of PK/PD modulation in up to 3&#xD;
      additional patients presenting with tumors expressing high levels of GR (GR-high) may be&#xD;
      performed at each dose level after the dose level has cleared the initial dose-limiting&#xD;
      toxicity evaluation period; these additional patients may serve as supplemental patients for&#xD;
      selection of the maximum tolerated dose and/or RP2D.&#xD;
&#xD;
      Dose expansion will further evaluate the safety and preliminary antitumor activity of&#xD;
      ORIC-101 in patients presenting with different levels of GR expressing-tumors.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 28, 2019</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Modified interval 3+3 dose escalation design, followed by dose expansion</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recommended Phase 2 Dose (RP2D)</measure>
    <time_frame>12 months</time_frame>
    <description>RP2D as determined by 3+3 dose escalation design</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PSA Response Rate</measure>
    <time_frame>36 months</time_frame>
    <description>≥50% decline from baseline at 8 weeks per Prostate Cancer Working Group 3 (PCWG3) criteria</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PSA Progression</measure>
    <time_frame>36 months</time_frame>
    <description>From study start until PCWG3 criteria is met</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with Adverse Events</measure>
    <time_frame>36 months</time_frame>
    <description>Safety and tolerability of ORIC-101 in combination with enzalutamide</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with Abnormal Laboratory Values</measure>
    <time_frame>36 months</time_frame>
    <description>Safety and tolerability of ORIC-101 in combination with enzalutamide</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with Abnormal 12-lead ECG</measure>
    <time_frame>36 months</time_frame>
    <description>Safety and tolerability of ORIC-101 in combination with enzalutamide</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with Abnormal Vital Signs</measure>
    <time_frame>36 months</time_frame>
    <description>Safety and tolerability of ORIC-101 in combination with enzalutamide</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration (Cmax)</measure>
    <time_frame>28 Days</time_frame>
    <description>PK of ORIC-101 in combination with enzalutamide</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum plasma concentration (Cmin)</measure>
    <time_frame>36 months</time_frame>
    <description>PK of ORIC-101 in combination with enzalutamide</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of maximum observed concentration (Tmax)</measure>
    <time_frame>28 Days</time_frame>
    <description>PK of ORIC-101 in combination with enzalutamide</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the curve (AUC(0-24))</measure>
    <time_frame>28 Days</time_frame>
    <description>PK of ORIC-101 in combination with enzalutamide</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination half-life (T1/2)</measure>
    <time_frame>28 Days</time_frame>
    <description>PK of ORIC-101 in combination with enzalutamide</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Circulating tumor cells (CTCs) conversion</measure>
    <time_frame>36 months</time_frame>
    <description>≥5 cells/7.5 mL of blood to 0 (zero) (CTC0), as well as from unfavorable (≥5 cells/7.5 mL of blood) to favorable (&lt;5 cells/7.5 mL of blood)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>36 months</time_frame>
    <description>Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and PCWG3 criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR)</measure>
    <time_frame>36 months</time_frame>
    <description>Radiographic progression using RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>36 months</time_frame>
    <description>Time from first dose to first documentation of radiographic progression or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>36 months</time_frame>
    <description>Time from first dose to death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with GR Expression by IHC</measure>
    <time_frame>36 months</time_frame>
    <description>Level of GR expression by IHC in tumor tissue samples</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Prostatic Neoplasms</condition>
  <arm_group>
    <arm_group_label>Dose Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ORIC-101 dosed orally, once per day in combination with enzalutamide (160 mg) of each 28-day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RP2D dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ORIC-101</intervention_name>
    <description>ORIC-101 once daily in each 28-day cycle</description>
    <arm_group_label>Dose Escalation</arm_group_label>
    <arm_group_label>Dose Expansion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>enzalutamide 40 MG oral capsule [Xtandi]</intervention_name>
    <description>160 mg once daily in each 28-day cycle</description>
    <arm_group_label>Dose Escalation</arm_group_label>
    <arm_group_label>Dose Expansion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed adenocarcinoma of the prostate&#xD;
&#xD;
          -  Metastatic prostate cancer currently being treated with enzalutamide (Xtandi®) 160 mg&#xD;
             once daily plus surgical or ongoing chemical castration, with baseline testosterone&#xD;
             level &lt;50 ng/dL&#xD;
&#xD;
          -  Must have been on treatment with enzalutamide for at least 3 months prior to&#xD;
             documented evidence of PSA progression defined as per PCWG3: minimum of 2 rising&#xD;
             values (3 measurements) obtained a minimum of one week apart with the latest result&#xD;
             being at least 2.0 ng/mL (or 1.0 ng/mL if PSA rise is the only indication of&#xD;
             progression)&#xD;
&#xD;
          -  Agreement and ability to undergo on-study core biopsies, as follows, through a&#xD;
             procedure that is deemed to be clinically feasible and not carry significant risk:&#xD;
&#xD;
               -  one pre-treatment tumor biopsy obtained while on treatment with enzalutamide&#xD;
                  prior to enrollment on this study; and&#xD;
&#xD;
               -  one post-treatment tumor biopsy during Cycle 2&#xD;
&#xD;
               -  one end of treatment tumor biopsy (optional)&#xD;
&#xD;
          -  ECOG performance status 0 or 1&#xD;
&#xD;
          -  Life expectancy of at least 3 months&#xD;
&#xD;
          -  Adequate organ function as defined by the following criteria:&#xD;
&#xD;
               -  ANC ≥1500 cells/mm3 (1.5 × 103 cells/mm3)&#xD;
&#xD;
               -  Platelets ≥100,000 /µL (100 × 109 /L)&#xD;
&#xD;
               -  Hemoglobin ≥9.0 g/dL (90 g/L)&#xD;
&#xD;
               -  AST (SGOT) or ALT (SGPT) ≤2.5 × ULN, ≤5.0 × ULN for patients with liver&#xD;
                  metastases&#xD;
&#xD;
               -  Bilirubin ≤1.5 × ULN; patients with a known history of Gilbert's syndrome and/or&#xD;
                  isolated elevations of indirect bilirubin are eligible&#xD;
&#xD;
               -  QTcF ≤480 msec&#xD;
&#xD;
          -  Capable of giving signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  No intervening therapy between enzalutamide treatment and enrollment on this study&#xD;
&#xD;
          -  Any other active malignancy, with the exception of adequately treated non-melanoma&#xD;
             skin cancer, adequately treated superficial bladder cancer, stage 1 or 2 solid tumor&#xD;
             malignancies without evidence of disease, or other solid tumors curatively treated&#xD;
             with no evidence of disease for ≥5 years from enrollment&#xD;
&#xD;
          -  Current treatment on another therapeutic clinical trial&#xD;
&#xD;
          -  Prior or current treatment with ORIC-101 or any other GR antagonist (eg, CORT-125281,&#xD;
             mifepristone, relacorilant)&#xD;
&#xD;
          -  Prior chemotherapy in the metastatic castration-resistant prostate cancer setting&#xD;
&#xD;
          -  Prior treatment with a second-generation AR modulator (eg, apalutamide, abiraterone,&#xD;
             darolutamide)&#xD;
&#xD;
          -  History of Cushing's syndrome or adrenal insufficiency&#xD;
&#xD;
          -  History or presence of CNS metastases&#xD;
&#xD;
          -  History of seizures or condition that may predispose to seizures&#xD;
&#xD;
          -  Current (at C1D1) or requirement for chronic use of systemic corticosteroids with the&#xD;
             exception of inhaled, topical, intraocular, intranasal, or intraarticular&#xD;
             corticosteroids&#xD;
&#xD;
          -  Current (within 10 days prior to first dose of ORIC-101) or expected on-study&#xD;
             treatment with specified strong CYP3A4 inhibitors or inducers&#xD;
&#xD;
          -  Receiving any other anticancer therapy, including radiotherapy within 21 days prior to&#xD;
             C1D1. Patients must have recovered from all toxicities from prior anticancer therapies&#xD;
             and/or radiotherapy&#xD;
&#xD;
          -  Major surgery within 21 days prior to C1D1 or incomplete recovery from adverse effects&#xD;
             resulting from such procedure&#xD;
&#xD;
          -  Known human immunodeficiency virus (HIV) infection, unless patient is healthy and has&#xD;
             a low risk of AIDS-related outcomes&#xD;
&#xD;
          -  Active Hepatitis B or C infection&#xD;
&#xD;
          -  Any other condition or circumstance (eg, clinical, psychological, familial,&#xD;
             sociological, inability to swallow oral study drug) that, in the opinion of the&#xD;
             investigator, may interfere with protocol compliance or contraindicates participation&#xD;
             in the study&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pratik S. Multani, MD</last_name>
    <role>Study Director</role>
    <affiliation>Oric Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rupal Patel, MS</last_name>
    <phone>650-388-5600</phone>
    <email>rupal.patel@oricpharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Edna Chow Maneval, PhD</last_name>
    <phone>650-388-5600</phone>
    <email>edna.chowmaneval@oricpharma.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emelei Klein</last_name>
      <phone>646-422-4358</phone>
    </contact>
    <investigator>
      <last_name>Abida Wasim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Carolina Urologic Research Center</name>
      <address>
        <city>Myrtle Beach</city>
        <state>South Carolina</state>
        <zip>29572</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katie Valipour</last_name>
      <phone>843-449-1010</phone>
      <phone_ext>268</phone_ext>
      <email>kvalipour@curcmb.com</email>
    </contact>
    <investigator>
      <last_name>Neal Shore, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>GUClinicalTrials@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Eleni Efstathiou, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 24, 2019</study_first_submitted>
  <study_first_submitted_qc>July 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 26, 2019</study_first_posted>
  <last_update_submitted>July 13, 2021</last_update_submitted>
  <last_update_submitted_qc>July 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

